BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 34502127)

  • 1. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease.
    Waheed Y; Yang F; Sun D
    Korean J Intern Med; 2021 Nov; 36(6):1281-1293. PubMed ID: 33045808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uric acid metabolism in pre-hypertension and the metabolic syndrome.
    Rizzo M; Obradovic M; Labudovic-Borovic M; Nikolic D; Montalto G; Rizvi AA; Mikhailidis DP; Isenovic ER
    Curr Vasc Pharmacol; 2014; 12(4):572-85. PubMed ID: 23627979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor?
    Nashar K; Fried LF
    Adv Chronic Kidney Dis; 2012 Nov; 19(6):386-91. PubMed ID: 23089273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.
    Yanai H; Katsuyama H; Hakoshima M; Adachi H
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High uric acid level is a risk factor for progression of IgA nephropathy with chronic kidney disease stage G3a.
    Moriyama T; Itabashi M; Takei T; Kataoka H; Sato M; Shimizu A; Iwabuchi Y; Nishida M; Uchida K; Nitta K
    J Nephrol; 2015 Aug; 28(4):451-6. PubMed ID: 25355499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease.
    Sellmayr M; Hernandez Petzsche MR; Ma Q; Krüger N; Liapis H; Brink A; Lenz B; Angelotti ML; Gnemmi V; Kuppe C; Kim H; Bindels EMJ; Tajti F; Saez-Rodriguez J; Lech M; Kramann R; Romagnani P; Anders HJ; Steiger S
    J Am Soc Nephrol; 2020 Dec; 31(12):2773-2792. PubMed ID: 32938648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S
    Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights.
    Mei Y; Dong B; Geng Z; Xu L
    Front Endocrinol (Lausanne); 2022; 13():911968. PubMed ID: 35909538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperuricemia, the heart, and the kidneys - to treat or not to treat?
    Petreski T; Ekart R; Hojs R; Bevc S
    Ren Fail; 2020 Nov; 42(1):978-986. PubMed ID: 32972284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrochemical analysis of uric acid excretion to the intestinal lumen: Effect of serum uric acid-lowering drugs and 5/6 nephrectomy on intestinal uric acid levels.
    Fujita K; Yamada H; Iijima M; Ichida K
    PLoS One; 2019; 14(12):e0226918. PubMed ID: 31891613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperuricemia and Cardiovascular Disease.
    Zhang S; Wang Y; Cheng J; Huangfu N; Zhao R; Xu Z; Zhang F; Zheng W; Zhang D
    Curr Pharm Des; 2019; 25(6):700-709. PubMed ID: 30961478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendrobium officinalis six nostrum ameliorates urate under-excretion and protects renal dysfunction in lipid emulsion-induced hyperuricemic rats.
    Chen X; Ge HZ; Lei SS; Jiang ZT; Su J; He X; Zheng X; Wang HY; Yu QX; Li B; Lv GY; Chen SH
    Biomed Pharmacother; 2020 Dec; 132():110765. PubMed ID: 33120237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baicalein alleviates hyperuricemia by promoting uric acid excretion and inhibiting xanthine oxidase.
    Chen Y; Zhao Z; Li Y; Yang Y; Li L; Jiang Y; Lin C; Cao Y; Zhou P; Tian Y; Wu T; Pang J
    Phytomedicine; 2021 Jan; 80():153374. PubMed ID: 33075645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different clinical impact of hyperuricemia according to etiologies of chronic kidney disease: Gonryo Study.
    Watanabe K; Nakayama M; Yamamoto T; Yamada G; Sato H; Miyazaki M; Ito S
    PLoS One; 2021; 16(3):e0249240. PubMed ID: 33765101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
    Uchida S; Kumagai T; Chang WX; Tamura Y; Shibata S
    Contrib Nephrol; 2018; 192():56-68. PubMed ID: 29393121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations Between Serum Uric Acid Concentrations and Cardiometabolic Risk and Renal Injury in Obese and Overweight Children.
    Özalp Kızılay D; Şen S; Ersoy B
    J Clin Res Pediatr Endocrinol; 2019 Sep; 11(3):262-269. PubMed ID: 30759960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Effects of Hyperuricemia.
    Méndez Landa CE
    Contrib Nephrol; 2018; 192():8-16. PubMed ID: 29393089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.